Everest Organics Secures Korean Drug Master File Approval for Rabeprazole Sodium API
Everest Organics Limited has obtained Drug Master File (DMF) approval from Korean authorities for its Rabeprazole Sodium API on February 18, 2025. This approval allows the company to export the API, used in treating excessive stomach acid conditions, to the South Korean market. The development marks a significant milestone in Everest Organics' international expansion efforts and opens up new revenue opportunities in the Korean pharmaceutical industry.